ABCC7 p.Cys76Ser

Predicted by SNAP2: A: N (72%), D: D (75%), E: D (75%), F: D (75%), G: D (66%), H: D (71%), I: D (66%), K: D (80%), L: D (75%), M: N (57%), N: D (66%), P: D (75%), Q: D (75%), R: D (80%), S: D (53%), T: D (53%), V: D (63%), W: D (80%), Y: D (75%),
Predicted by PROVEAN: A: N, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: N, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Chen EY, Bartlett MC, Loo TW, Clarke DM
The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
J Biol Chem. 2004 Sep 17;279(38):39620-7. Epub 2004 Jul 21., 2004-09-17 [PMID:15272010]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mense M, Vergani P, White DM, Altberg G, Nairn AC, Gadsby DC
In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer.
EMBO J. 2006 Oct 18;25(20):4728-39. Epub 2006 Oct 12., 2006-10-18 [PMID:17036051]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Alexander C, Ivetac A, Liu X, Norimatsu Y, Serrano JR, Landstrom A, Sansom M, Dawson DC
Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore.
Biochemistry. 2009 Oct 27;48(42):10078-88., 2009-10-27 [PMID:19754156]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Serrano JR, Liu X, Borg ER, Alexander CS, Shaw CF 3rd, Dawson DC
CFTR: Ligand exchange between a permeant anion ([Au(CN)2]-) and an engineered cysteine (T338C) blocks the pore.
Biophys J. 2006 Sep 1;91(5):1737-48. Epub 2006 Jun 9., [PMID:16766608]

Abstract [show]
Comments [show]
Sentences [show]